Oppenheimer Holdings Comments on Endo International PLC’s FY2017 Earnings (ENDP)

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Oppenheimer Holdings increased their FY2017 earnings per share estimates for Endo International PLC in a report released on Monday. Oppenheimer Holdings analyst D. Archila now forecasts that the company will post earnings of $3.56 per share for the year, up from their prior forecast of $3.52. Oppenheimer Holdings currently has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q1 2018 earnings at $0.66 EPS, Q2 2018 earnings at $0.66 EPS, FY2020 earnings at $3.68 EPS and FY2021 earnings at $3.91 EPS.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The business had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 earnings per share.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/10/13/oppenheimer-holdings-comments-on-endo-international-plcs-fy2017-earnings-endp.html.

ENDP has been the topic of a number of other research reports. Royal Bank Of Canada set a $15.00 price objective on Endo International PLC and gave the stock a “hold” rating in a research note on Sunday, July 16th. BidaskClub upgraded Endo International PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Zacks Investment Research lowered Endo International PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Deutsche Bank AG lowered their price objective on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, July 7th. Finally, Cantor Fitzgerald assumed coverage on Endo International PLC in a research note on Friday, June 16th. They set a “neutral” rating and a $12.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the stock. Endo International PLC currently has an average rating of “Hold” and a consensus target price of $12.64.

In related news, CEO Paul Campanelli bought 6,500 shares of the business’s stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $7.71 per share, with a total value of $50,115.00. Following the acquisition, the chief executive officer now owns 213,620 shares of the company’s stock, valued at $1,647,010.20. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, COO Terrance J. Coughlin bought 20,000 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were bought at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Insiders have acquired a total of 36,000 shares of company stock worth $279,460 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. James Investment Research Inc. acquired a new position in shares of Endo International PLC in the 2nd quarter valued at about $113,000. Blair William & Co. IL acquired a new position in shares of Endo International PLC in the 2nd quarter valued at about $126,000. Point View Wealth Management Inc. lifted its stake in shares of Endo International PLC by 16.6% in the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after purchasing an additional 1,900 shares during the period. Riverhead Capital Management LLC lifted its stake in shares of Endo International PLC by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after purchasing an additional 5,887 shares during the period. Finally, Bank of Hawaii acquired a new position in shares of Endo International PLC in the 2nd quarter valued at about $180,000. 90.71% of the stock is currently owned by hedge funds and other institutional investors.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply